semaglutide weight loss trial Overview of body-weight loss in the STEP trials. The STEP programme

SELECT Trial: Semaglutide reduces the risk of MACE by 20% in people with overweight or obesity, pre-existing CVD, and no diabetes. Average weight loss of -9.4% at 51 months

29.02

★★★★☆4.8 (126)

Higher-dose oral semaglutide may be beneficial option for type 2 diabetes, obesity

29.96

★★★★★4.9 (98)

Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial

20.65

★★★★★5.0 (157)

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

28.57

★★★★★4.7 (84)

Wegovy confers reductions in cardiovascular risk, regardless of weight loss

26.18

★★★★★4.9 (203)

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

21.59

★★★★★5.0 (176)

Sound Weight Loss | The SURMOUNT-5 trial just confirmed it: tirzepatide outperformed semaglutide 20.2% vs 13.7% weight loss over 72 weeks. That is nearly 50%

22.96

★★★★★4.8 (132)